Adults 18 to 60, any sex, with Relapsing-remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Time to First RelapsePrimary· Baseline up to 96 weeks
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. These new or worsening symptoms should be noted by subject and must be accompanied by at least 1 of the following: An increase of greater than or equal to (\>=) 1 grade in \>=2 functional scales of the Expanded Disability Status Scale (EDSS) or an increase of \>=2 grades in 1 functional scale of the EDSS or an i
25th Percentile
Group
Value
95% CI
Rebif®
332.0
± 10.9
Copaxone®
290.0
± 9.5
30th Percentile
Group
Value
95% CI
Rebif®
495.0
± 16.3
Copaxone®
432.0
± 14.2
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT02064816 — A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
· Phase 4
· completed
NCT01791244 — A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subje
· Phase 4
· completed
Other recruiting trials for Relapsing-remitting Multiple Sclerosis
Currently open trials in the same condition.
NCT05758831 — RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
· Phase 3
· recruiting
NCT05755061 — WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
· Phase 1
· active not recruiting
NCT06586177 — Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
· recruiting
Other EMD Serono trials
Trials by the same sponsor.
NCT02070978 — Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
· Phase 2
· terminated
NCT01971515 — First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
· Phase 1
· completed
NCT01992874 — Relative Bioavailability of Pimasertib in Cancer Patients
· Phase 1
· completed
NCT01936363 — Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
· Phase 2
· completed
NCT01693068 — Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EMD Serono
Last refreshed: 27 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00078338.